These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 14987898)
21. The impact of globalization on vaccine development and availability. Milstien JB; Kaddar M; Kieny MP Health Aff (Millwood); 2006; 25(4):1061-9. PubMed ID: 16835187 [TBL] [Abstract][Full Text] [Related]
22. Win-win interactions between the public and private sectors. Batson A Nat Med; 1998 May; 4(5 Suppl):487-91. PubMed ID: 9585192 [No Abstract] [Full Text] [Related]
23. [Towards a new vaccine economy?]. Poirot P; Martin JF Sante; 1994; 4(3):183-7. PubMed ID: 7921683 [TBL] [Abstract][Full Text] [Related]
24. The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization. Kane MA; Hadler SC; Lee L; Shapiro CN; Cui F; Wang X; Kumar R Vaccine; 2013 Dec; 31 Suppl 9():J15-20. PubMed ID: 24331015 [TBL] [Abstract][Full Text] [Related]
25. The NIH, research institutions and industry: working together on a shared goal. Omary MB Gastroenterology; 2007 May; 132(5):1647-50. PubMed ID: 17484859 [No Abstract] [Full Text] [Related]
26. Michigan's next wave of biopharmaceutical entrepreneurship. Kerppola R; van de Walle M; Surine S Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575 [No Abstract] [Full Text] [Related]
27. Hepatitis B Vaccine in national immunization schedule: a preventive step in India. Verma R; Khanna P; Prinja S; Rajput M; Chawla S; Bairwa M Hum Vaccin; 2011 Dec; 7(12):1387-8. PubMed ID: 22134433 [TBL] [Abstract][Full Text] [Related]
28. Key drivers behind the development of global vaccine market. Gréco M Vaccine; 2001 Feb; 19(13-14):1606-10. PubMed ID: 11166882 [No Abstract] [Full Text] [Related]
29. Pharmaceutical funding decisions must balance therapeutic innovation, opportunity costs and patient equity. Ragupathy R; Jameson M N Z Med J; 2016 Aug; 129(1440):22-4. PubMed ID: 27538036 [No Abstract] [Full Text] [Related]
30. Funding medical and health-related research in the public interest. Baird PA CMAJ; 1996 Aug; 155(3):299-301. PubMed ID: 8705910 [TBL] [Abstract][Full Text] [Related]
31. Immunization for hepatocellular carcinoma. Karthikeyan G Indian Pediatr; 1997 Dec; 34(12):1141-3. PubMed ID: 9715567 [No Abstract] [Full Text] [Related]
35. [Cost-benefits of vaccination against hepatitis B in hospital personnel in Venezuela]. Fernández Barboza R; Rivero D; Echeverría B; Machado IV Bol Oficina Sanit Panam; 1991 Jul; 111(1):16-23. PubMed ID: 1834080 [TBL] [Abstract][Full Text] [Related]
36. [Efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma]. Li RC; Yang JY; Gong J; Li YP; Huang ZN; Fang KX; Xu ZY; Liu CB; Zhao K; Zhuang H Zhonghua Liu Xing Bing Xue Za Zhi; 2004 May; 25(5):385-7. PubMed ID: 15231157 [TBL] [Abstract][Full Text] [Related]
37. Vaccine manufacturing: challenges and solutions. Ulmer JB; Valley U; Rappuoli R Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488 [TBL] [Abstract][Full Text] [Related]
38. Vaccine venture boosts health hopes. Butler D Nature; 2009 Sep; 461(7262):323. PubMed ID: 19759588 [No Abstract] [Full Text] [Related]
39. WHO expectation and industry goals. Vandersmissen W Vaccine; 2001 Feb; 19(13-14):1611-5. PubMed ID: 11166883 [TBL] [Abstract][Full Text] [Related]
40. The winning shot. New vaccine technologies to offer pinpoint attacks on a variety of potentially deadly diseases. Kirchheimer B Mod Healthc; 2005 Nov; 35(46):52-4. PubMed ID: 16334833 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]